Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note released on Friday. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Trading Up 3.3 %

Brainstorm Cell Therapeutics stock opened at $1.86 on Friday. The stock has a market capitalization of $10.60 million, a price-to-earnings ratio of -0.39 and a beta of 0.26. The stock has a 50 day moving average of $1.99 and a two-hundred day moving average of $2.64. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.